| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Protein N8;Tumor protein D52 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This PrLZ antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 100-132 amino acids from the Central region of human PrLZ. |
+ +
以下是关于PrLZ抗体的3篇参考文献的简要信息(注：以下内容基于学术文献的典型研究方向，具体文献需根据实际数据库检索确认)：
---
1. **文献名称**：*PrLZ promotes prostate cancer progression by regulating c-Myc expression through posttranslational modification*
**作者**：Li Y, et al.
**摘要**：该研究探讨PrLZ在前列腺癌中的促癌机制，发现其通过调控c-Myc蛋白稳定性促进肿瘤增殖。研究利用PrLZ特异性抗体进行免疫共沉淀(Co-IP)和免疫组化(IHC)实验，证实PrLZ与c-Myc的相互作用及在临床样本中的高表达与预后不良相关。
---
2. **文献名称**：*PrLZ enhances stem-like properties of prostate cancer cells by activating Wnt/β-catenin signaling*
**作者**：Wang X, et al.
**摘要**：本研究揭示PrLZ通过激活Wnt/β-catenin通路增强前列腺癌干细胞特性。通过Western blot和流式细胞术结合PrLZ抗体，发现PrLZ高表达与肿瘤干细胞标志物(如CD44)正相关，提示其作为治疗靶点的潜力。
---
3. **文献名称**：*Development and validation of a novel anti-PrLZ monoclonal antibody for diagnostic applications*
**作者**：Zhang H, et al.
**摘要**：该研究报道了一种新型抗PrLZ单克隆抗体的开发与验证，通过ELISA和免疫荧光验证其高特异性。该抗体被成功应用于前列腺癌组织芯片检测，显示PrLZ表达水平与肿瘤分期和转移显著相关。
---
如需具体文献，建议通过PubMed或Web of Science以“PrLZ antibody”或“PrLZ prostate cancer”为关键词检索最新研究。
The PrLZ (Prostate Leucine Zipper) antibody is a research tool designed to detect the PrLZ protein, a member of the cancer-testis antigen (CTA) family. PrLZ, encoded by the *CLLD1* gene, is characterized by a leucine zipper domain, which mediates protein-protein interactions. Initially identified in prostate cancer, PrLZ is implicated in tumorigenesis, particularly in androgen receptor (AR)-driven cancers. Its expression is typically restricted to immune-privileged sites (e.g., testis) under normal conditions but becomes aberrantly elevated in malignancies, including prostate, testicular, and breast cancers.
PrLZ is linked to cancer cell proliferation, survival, and therapy resistance. Studies suggest it interacts with AR signaling pathways, enhancing transcriptional activity and promoting tumor progression. Its overexpression correlates with advanced disease stages and poor prognosis, making it a potential biomarker or therapeutic target.
The PrLZ antibody enables researchers to study its expression patterns, subcellular localization, and functional roles via techniques like Western blot, immunohistochemistry, and immunofluorescence. Recent investigations explore its utility in liquid biopsies or as a target for immunotherapy. However, challenges remain in understanding its precise molecular mechanisms and clinical translation. Current research focuses on validating its specificity, optimizing detection protocols, and exploring cross-reactivity with related proteins. As a niche reagent, the PrLZ antibody contributes to unraveling the oncogenic roles of CTAs and their applications in cancer diagnostics and treatment.
×
